alk-abello a/s (AKBLF) Key Developments
ALK-Abelló A/S Presents at 7th Kempen & Co Healthcare/Life Sciences Conference, Apr-01-2014
Apr 3 14
ALK-Abelló A/S Presents at 7th Kempen & Co Healthcare/Life Sciences Conference, Apr-01-2014 . Venue: Amsterdam, Netherlands.
ALK-Abelló A/S Revises Earnings Guidance for the Year 2014
Mar 20 14
ALK-Abelló A/S revises earnings guidance for the year 2014. The company announced that the milestone payment will be booked as revenue from SLIT-Tablets in North America and the company now expects operating profit (EBITDA) to be DKK 300-400 million before special items, income from product supply, and potential sales royalties in North America against previously provided guidance of DKK 225-400 million. The higher end of this range assumes two additional product development milestone payments from Merck.
Alk-Abelló A/S Approves Ordinary Dividend
Mar 13 14
ALK-Abelló A/S approved ordinary dividend of DKK 5.00 per share at the annual general meeting held on 12 March 2014.
Alk and Torii Announce Positive Phase II/III Results from Japan Trial of Anti-Allergen
Mar 12 14
Torii Pharmaceutical and its Danish development partner ALK Abello have announced positive results from a Phase II/III clinical study of investigational drug TO-203. The drug candidate is a sublingual tablet investigated as an allergen immunotherapy for house dust mite allergy in patients with allergic rhinitis. The companies said TO-203 has met the primary endpoint of providing statistically significant improvement in total combined rhinitis score (TCRS) compared to placebo, in patients with house dust mite-induced allergic rhinitis.
ALK-Abelló A/S Proposes Amendments to Articles of Association
Feb 14 14
ALK-Abelló A/S announced that at the Annual General Meeting to be held on March 12, 2014, the Board of Directors will propose that the Chairman and the Vice Chairman of the Board shall in future be elected by the general meeting rather than by the present procedure, whereby the Board selects its own Chairman and Vice Chairman. This proposal means that article 8.1 of the Articles of Association will be amended.